130 related articles for article (PubMed ID: 3477462)
21. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
[TBL] [Abstract][Full Text] [Related]
23. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
[TBL] [Abstract][Full Text] [Related]
24. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
25. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse.
Morse M; Savitch J; Balis F; Miser J; Feusner J; Reaman G; Poplack D; Bleyer A
J Clin Oncol; 1985 Jan; 3(1):19-24. PubMed ID: 3855310
[TBL] [Abstract][Full Text] [Related]
26. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
27. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
28. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
29. [Clinical pharmacology of methotrexate (MTX)--altered central nervous system pharmacology of MTX with meningial relapse of childhood leukemia].
Matsuoka H; Sasaki K; Fujimoto T
Rinsho Ketsueki; 1986 Oct; 27(10):1856-61. PubMed ID: 3469425
[No Abstract] [Full Text] [Related]
30. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
[TBL] [Abstract][Full Text] [Related]
31. [Effect of cranial irradiation on the blood-cerebrospinal fluid and blood-brain barrier].
Ludwig R
Klin Padiatr; 1987; 199(3):233-8. PubMed ID: 3476804
[TBL] [Abstract][Full Text] [Related]
32. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
Mandal P; Samaddar S; Chandra J; Parakh N; Goel M
Indian J Hematol Blood Transfus; 2020 Jul; 36(3):498-504. PubMed ID: 32647424
[TBL] [Abstract][Full Text] [Related]
33. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
34. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
35. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
[TBL] [Abstract][Full Text] [Related]
36. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
37. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
38. Correlation of cerebrospinal fluid beta-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate.
Vlacha V; Eliopoulou M; Haidas S; Beratis NG
Pediatr Blood Cancer; 2004 Apr; 42(4):350-6. PubMed ID: 14966832
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate.
Lena N; Imbert AM; Favre R; Cano JP; Carcassonne Y
Eur J Cancer Clin Oncol; 1987 May; 23(5):481-5. PubMed ID: 3477455
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]